Diffuse Large B-Cell Lymphoma News

News

IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization

04/19/2024

Amber Denham

According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...

According to phase 2 results,...

04/19/2024

Oncology

News

Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma

04/09/2024

Amber Denham

According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.

According to phase 2 data, short...

04/09/2024

Oncology

News

Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL

02/28/2024

Amber Denham

According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...

According to 2-year follow-up...

02/28/2024

Oncology

News

Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

02/21/2024

Amber Denham

Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.

Polatuzumab vedotin with...

02/21/2024

Oncology

News

Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL

02/02/2024

Amber Denham

Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.

Blinatumomab consolidation after...

02/02/2024

Oncology

News

Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL

01/11/2024

Amber Denham

The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.

The combination of rituximab and...

01/11/2024

Oncology

News

Controlling Nutritional Status Score Shows Prognostic Value Among Older Patients With DLBCL

01/03/2024

Amber Denham

Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.

Prognostic value was found in...

01/03/2024

Oncology

News

CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy

01/03/2024

Amber Denham

A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.

A CD5 gene expression signature...

01/03/2024

Oncology

Conference Coverage

R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL

12/11/2023

Amber Denham

Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.

Efficacy results of the phase 2...

12/11/2023

Oncology

Conference Coverage

Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses Among Pretreated Patients With DLBCL, Including HGBCL

12/11/2023

Amber Denham

Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...

Glofitamab plus polatuzumab...

12/11/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology